The objectives of the AtheroGene study: * To assess the value of clinical and molecular biomarkers for secondary prevention in patients with coronary artery disease. * To assess risk prediction across a wide range of coronary artery disease phenotypes with particular emphasis on the role of genetics. * The major endpoint in this study was cardiovascular death and non-fatal myocardial infarction among other cardiovascular outcomes.
- Start Year
- End Year
- Stiftung Rheinland-Pfalz für Innovation, Ministry for Science and Education, Mainz, Germany (AZ 15202-386261/545); INSERM, Paris (to Dr. Blankenberg), and the Schleicher Stiftung, Dresdner Bank, Frankfurt, Germany.
- Study design
- Population cohort
- Follow Up
- Median follow-up period of 4.2 years
Zengin E, Bickel C, Schnabel RB, Zeller T,Lackner K-J, Rupprecht H-J, et al. (2015) Risk Factors of Coronary Artery Disease in Secondary Prevention—Results from the AtheroGene—Study. PLoS ONE 10(7): e0131434. doi:10.1371/journal.pone.0131434
- Sources of Recruitment
Number of participants
- Number of participants
- Number of participants with biosamples
- Supplementary Information
- Patients with suspected coronary artery disease
Availability of data and biosamples
No coverage data about the variables classifications are available.